CD40 and neoplasm: These results were similar to our previous CD40 mAb biodistribution study in 4T1 tumor model.[23b] Overall, these data suggest that the local controlled release of CD40 agonist mAb via NDES protected the mice from undesirable systemic drug exposure and its associated TRAE, presenting a safer treatment modality.